SCHEMBL6838801

SCHEMBL6838801

[CH2]C(C(=O)c1ccccc1)c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
LMNA P02545 6/20 0.59
CES2 O00748 3/20 0.59
CES1 P23141 3/20 0.59
ALDH1A1 P00352 4/20 0.48
CYP3A4 P08684 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
MDM2 Q00987 1/20 0.45
CYP2D6 P10635 1/20 0.44
SRC P12931 1/20 0.44
DAO P14920 1/20 0.44
TSHR P16473 1/20 0.44
NAPRT Q6XQN6 1/20 0.44
MAPK1 P28482 1/20 0.43
MITF O75030 1/20 0.42
HTT P42858 1/20 0.42
RAB9A P51151 1/20 0.42
GFER P55789 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1167722 0.79 L3MBTL1 (0.52) TDP1L3MBTL1LMNACES2CES1
SCHEMBL28960147 0.78 TDP1 (0.56) TDP1L3MBTL1LMNACES2CES1
SCHEMBL727901 0.78 SRC (0.56) TDP1L3MBTL1LMNACES2CES1
SCHEMBL4380823 0.76 CES1 (0.58) TDP1L3MBTL1LMNACES2CES1
SCHEMBL2927912 0.76 L3MBTL1 (1.00) TDP1L3MBTL1LMNACES2CES1
SCHEMBL1667152 0.76 TDP1 (0.67) TDP1L3MBTL1LMNACES2CES1
SCHEMBL29719387 0.76 TDP1 (0.59) TDP1L3MBTL1LMNACES2CES1
Benzoin SCHEMBL29167409 0.76 LMNA (0.91) TDP1L3MBTL1LMNACES2CES1
Benzoin SCHEMBL10646810 0.76 LMNA (0.91) TDP1L3MBTL1LMNACES2CES1
Benzoin SCHEMBL27562303 0.76 LMNA (0.91) TDP1L3MBTL1LMNACES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0531382-A1 N-SUBSTITUTED-1,2,4-TRIAZOLONE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS G.D. SEARLE & CO. (US) 1993-03-17 EP claimed
US-11702571-B2 Adhesive sheet for temporary fixation and method of manufacturing semiconductor device using the same LG CHEM, LTD. (KR) 2023-07-18 US disclosed
CN-111655811-B Adhesive sheet for temporary attachment and method of manufacturing semiconductor device using the same 株式会社LG化学 2022-04-15 CN disclosed
CN-111225963-B Adhesive sheet for temporary fixation and method for manufacturing semiconductor device using the same 株式会社LG化学 2022-02-22 CN disclosed
US-20210171802-A1 ADHESIVE SHEET FOR TEMPORARY FIXATION AND METHOD OF MANUFACTURING SEMICONDUCTOR DEVICE USING THE SAME LG CHEM, LTD. (KR) 2021-06-10 US disclosed
CN-111655811-A Adhesive sheet for temporary attachment and method of manufacturing semiconductor device using the same 株式会社LG化学 2020-09-11 CN disclosed
CN-111225963-A Adhesive sheet for temporary fixation and method for manufacturing semiconductor device using the same 株式会社LG化学 2020-06-02 CN disclosed
WO-2019199085-A1 ADHESIVE SHEET FOR TEMPORARY ATTACHMENT AND SEMICONDUCTOR DEVICE PRODUCING METHOD USING SAME 주식회사 엘지화학 2019-10-17 WO disclosed
WO-2019190242-A1 ADHESIVE SHEET FOR TEMPORARY FIXING, AND METHOD FOR PRODUCING SEMICONDUCTOR DEVICE BY USING SAME 주식회사 엘지화학 2019-10-03 WO disclosed
US-6753410-B2 ANALYZING THE PROCESSING OF AMYLOID PROTEIN PRECURSOR (APP); ALZHEIMER'S DISEASE; ENZYME INHIBITORS OF GAMMA-SECRETASE, A PROTEASE, AND INHIBITS PROTEOLYSIS OF PRESENILIN-1 ON WHICH THE SECRETASE ACTIVITY IS DEPENDENT MERCK & CO., INC. 2004-06-22 US disclosed
US-20020013276-A1 Investigational compounds MERCK & CO., INC. 2002-01-31 US disclosed
EP-0531382-A1 N-SUBSTITUTED-1,2,4-TRIAZOLONE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS G.D. SEARLE & CO. (US) 1993-03-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013276-A1 Investigational compounds CBR1, CBR3, CNR1 TDP1 2634/4885L3MBTL1 2299/4885LMNA 2279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.